新股消息 | 欧林生物(688319.SH)递表港交所

Group 1 - The core viewpoint of the article is that Chengdu Olymvax Biopharmaceuticals Inc. has submitted an application to list on the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [1] - Olymvax is described as a globally-oriented, innovation-driven biopharmaceutical company focused on the research, development, production, and commercialization of innovative vaccines [1] - Unlike many biotechnology companies that have yet to generate revenue, Olymvax has a mature and robust commercialization platform, having successfully commercialized three products: adsorbed tetanus vaccine, Haemophilus influenzae type b conjugate vaccine, and group A and C meningococcal polysaccharide conjugate vaccine [1]